TAO Synergies (TAOX) Gains from Investment Securities (2020 - 2026)
TAO Synergies' (TAOX) quarterly Gains from Investment Securities came in at -$6000.0 in Q2 2026, down 100.04% on a YoY basis from $14.5 million in Q2 2025, and down 200.0% quarter-over-quarter from $6000.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Gains from Investment Securities (2020 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Gains from Investment Securities for 6 consecutive years, with -$6000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gains from Investment Securities fell 100.04% year-over-year to -$6000.0; the trailing twelve-month figure through Jun 2026 stood at $5.8 million (down 58.53% YoY), and the FY2025 full-year result was $12.4 million, up 1398.02% from the prior year.
- Gains from Investment Securities declined to -$6000.0 in Q2 2026 per TAOX's latest filing, from $6000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $14.5 million in Q2 2025 and bottomed at -$8.4 million in Q4 2022.
- Historically, Gains from Investment Securities has averaged $628329.9 across 5 years, with a median of $0.0 in 2026.
- The widest YoY moves for Gains from Investment Securities: up 9325.76% in 2025, down 2229.31% in 2025.
- Over 5 years, Gains from Investment Securities stood at -$8.4 million in 2022, then soared by 96.25% to -$315000.0 in 2023, then soared by 263.49% to $515000.0 in 2024, then slumped by 223.69% to -$637000.0 in 2025, then jumped by 99.06% to -$6000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$6000.0, $6000.0, and -$637000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | -637,000.00 |
| Sep 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 14.52 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | 515,000.00 |
| Sep 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | -315,000.00 |
| Sep 30, 2023 | -674,000.00 |
| Jun 30, 2023 | 207,000.00 |
| Mar 31, 2023 | -588,000.00 |
| Dec 31, 2022 | -8.41 Mn |
| Mar 31, 2022 | 71,603.00 |
| Sep 30, 2020 | 1.70 Mn |